Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613

Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627

Published:2022-11-07 Issue:12 Volume:38 Page:2237-2240
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Young-Xu Yinong¹,Melsheimer Richard²,Emond Bruno³,Lefebvre Patrick³,DerSarkissian Maral⁴,Lax Angela⁵,Nguyen Catherine⁴,Bhak Rachel H.⁵,Wu Melody⁵^ORCID,Lin Iris⁶

Affiliation:

1. White River Junction VA Medical Center, White River Junction, VT, USA

2. Janssen Biologics BV, Leiden, the Netherlands

3. Analysis Group, Inc, Montréal, Québec, Canada

4. Analysis Group, Inc, Montréa, Québec, Canada

5. Analysis Group, Inc, Los Angeles, CA, USA

6. Analysis Group, Inc., Boston, MA, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2139970

Reference25 articles.

1. Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627

2. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab

3. Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding

4. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study

5. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France